PCI Biotech Q3 2021 interim results
17 nov. 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 17 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to Q3 2021 result presentation
09 nov. 2021 06h50 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 9 November 2021 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q3 2021 results on Wednesday 17 November 2021 at Oslo Cancer Cluster Innovation Park. Time:...
PCI Biotech to present at the 9th International mRNA Health Conference
09 nov. 2021 03h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 9 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
08 nov. 2021 05h15 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech: Employee share option scheme
06 sept. 2021 12h20 HE
|
PCI Biotech Holding ASA
Oslo, 6 September 2021 In accordance with the authorisation granted and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech...
PCI Biotech first half-year 2021 interim results
31 août 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 31 August 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year 2021 results. Please find enclosed the report and...
PCI Biotech: Invitation to first half-year 2021 result presentation
23 août 2021 04h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 23 August 2021 - PCI Biotech’s (OSE: PCIB) first half-year 2021 interim report will be released on 31 August 2021 at 07.00 CEST. The interim report and presentation will be made...
PCI Biotech: US patent for the vaccine technology (fimaVacc) in combination with checkpoint inhibitors
31 mai 2021 05h16 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
28 mai 2021 08h51 HE
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
PCI Biotech Minutes from Annual General Meeting 2021
28 mai 2021 05h24 HE
|
PCI Biotech Holding ASA
Oslo, 28 May 2021. The Annual General Meeting in PCI Biotech Holding ASA took place today, 28 May 2021. All proposals were resolved by the Annual General Meeting as presented in the notice convening...